Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease

Journal of Diabetes and its Complications

Volumn 29, Issue 3, 2015, Pages 433-437

  Thethi, Tina K ^a,b   Bajwa, Muhammad A ^c   Ghanim, Husam ^d   Jo, Chanhee ^e   Weir, Monica ^e   Goldfine, Allison B ^c,f   Umpierrez, Guillermo ^g   Desouza, Cyrus ^h   Dandona, Paresh ^d   Fang Hollingsworth, Ying ^e   Raghavan, Vasudevan ^e   Fonseca, Vivian A ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Southeast Louisiana Veterans Health Care System   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d Diabetes Endocrinology Center of Western NY   (United States)

^e SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Chronic kidney disease; Diabetes mellitus; Endothelial dysfunction; Inflammation; Paricalcitol

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PARICALCITOL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; ERGOCALCIFEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; BRACHIAL ARTERY; CHRONIC KIDNEY DISEASE; CHRONOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; FEMALE; FLOW MEDIATED DILATATION; GLUCOSE BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; MIDDLE AGED; MULTICENTER STUDY; NITROGLYCERINE MEDIATED DILATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ERGOCALCIFEROLS; FEMALE; HUMANS; INFLAMMATION; INSULIN; MALE; MIDDLE AGED; PLACEBOS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84925374962     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.01.004     Document Type: Article

References (22)

1. S.G. Achinger, and J.C. Ayus The role of vitamin D in left ventricular hypertrophy and cardiac function Kidney International. Supplement 2005 S37 S42
2. A.J. Brown, and D.W. Coyne Vitamin D analogs: New therapeutic agents for secondary hyperparathyroidism Treatments in Endocrinology 1 2002 313 327
3. N. Chitalia, T. Ismail, L. Tooth, F. Boa, G. Hampson, and D. Goldsmith Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients PLoS One 9 2014 e91363
4. M. Chonchol, M. Cigolini, and G. Targher Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction Nephrology, Dialysis, Transplantation 23 2008 269 274
5. M.C. Corretti, T.J. Anderson, E.J. Benjamin, D. Celermajer, F. Charbonneau, and M.A. Creager Force IBART: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force Journal of the American College of Cardiology 39 2002 257 265
6. D. Duplancic, M. Cesarik, N.K. Poljak, M. Radman, V. Kovacic, and J. Radic The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection Clinical Interventions in Aging 8 2013 149 156
7. V. Fonseca, C. Desouza, S. Asnani, and I. Jialal Nontraditional risk factors for cardiovascular disease in diabetes Endocrine Reviews 25 2004 153 175
8. E. Giovannucci, Y. Liu, B.W. Hollis, and E.B. Rimm 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study Archives of Internal Medicine 168 2008 1174 1180
9. E. Gonzalez-Parra, J. Rojas-Rivera, J. Tuñón, M. Praga, A. Ortiz, and J. Egido Vitamin D receptor activation and cardiovascular disease Nephrology, Dialysis, Transplantation 27 Suppl. 4 2012 iv17 iv21
10. A. Jawa, S. Nachimuthu, M. Pendergrass, S. Asnani, and V. Fonseca Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy Journal of Clinical Endocrinology and Metabolism 91 2006 31 35
11. C. Joergensen, L. Tarnow, J.P. Goetze, and P. Rossing Vitamin D analogue therapy, cardiovascular risk and kidney function in people with type 1 diabetes mellitus and diabetic nephropathy: A randomized trial Diabetic Medicine 2014 1 8 10.1111/dme.12606
12. C. McGreevy, and D. Williams New insights about vitamin D and cardiovascular disease: A narrative review Annals of Internal Medicine 155 2011 820 826
13. J.F. Navarro-González, J. Donate-Correa, M.L. Méndez, M.M. de Fuentes, J. García-Pérez, and C. Mora-Fernández Anti-inflammatory profile of paricalcitol in hemodialysis patients: A prospective, open-label, pilot study Journal of Clinical Pharmacology 53 2013 421 426
14. A. Ortiz, M.D. Sanchez Niño, J. Rojas, and J. Egido Paricalcitol for reduction of albuminuria in diabetes Lancet 377 2011 635 636 (author reply 636-637)
15. A.G. Pittas, B. Dawson-Hughes, T. Li, R.M. Van Dam, W.C. Willett, and J.E. Manson Vitamin D and calcium intake in relation to type 2 diabetes in women Diabetes Care 29 2006 650 656
16. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334
17. G.A. Reinhart Vitamin D analogs: Novel therapeutic agents for cardiovascular disease? Current Opinion in Investigational Drugs 5 2004 947 951
18. M.D. Sanchez-Niño, M. Bozic, E. Córdoba-Lanús, P. Valcheva, O. Gracia, and M. Ibarz Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy American Journal of Physiology. Renal Physiology 302 2012 F647 F657
19. Y. Slinin, A. Ishani, T. Rector, P. Fitzgerald, R. MacDonald, and J. Tacklind Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: A systematic review for a KDOQI clinical practice guideline American Journal of Kidney Diseases 60 2012 747 769
20. S.I. Sokol, V. Srinivas, J.P. Crandall, M. Kim, G. Tellides, and A.H. Lebastchi The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease Vascular Medicine 17 2012 394 404
21. J.R. Wu-Wong, M. Nakane, L. Traylor, X. Ruan, P.E. Kroeger, and J. Tian Cardiovascular disease in chronic kidney failure: Is there a role for vitamin D analogs? Current Opinion in Investigational Drugs 6 2005 245 254
22. C. Zoccali, G. Curatola, V. Panuccio, R. Tripepi, P. Pizzini, and M. Versace Paricalcitol and endothelial function in chronic kidney disease trial Hypertension 64 2014 1005 1011